Japanese Pegylated Interferon (PegIFN) Alfa-2b/Ribavirin (RBV) Combination Trial
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The aim of this trial is to evaluate the safety and efficacy of BI 201335 given for 12 or 24
weeks in combination with PegIFN alfa-2b/RBV given for 24 or 48 weeks in chronic genotype 1
hepatitis C virus infected treatment-naïve and treatment-experienced Japanese patients